title: [Serum autoantibodies profiling and early-stage cancer detection].
abstract: It is now well established that an immune response to cancer is elicited in humans, as demonstrated in part by the identification of autoantibodies against a number of tumor-associated antigens in sera from patients with different types of cancer. During these past few years, proteomic approaches have been developed to identify tumor-associated antigens and their cognate autoantibodies. Detection of a panel of serum autoantibodies has thus been proposed as a new method for early cancer diagnosis. Early detection seems to be particularly adequate in high-risk populations, such as heavy smokers for lung cancer or in women with high mammographic density for breast cancer. In this review, we highlight the features of serum autoantibody biomarkers and outline the proteomic strategies employed to identify and validate their use in clinical practice for cancer screening and diagnosis. We particularly emphasize the clinical utility of autoantibody signatures, using the examples of lung and breast cancer. Finally, we discuss the challenges remaining for clinical validation.
authors: CHU Montpellier, Laboratoire de biologie cellulaire et hormonale, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen Giraud, Montpellier, F-34295, France.
authors: Caroline
authors: C
authors: Desmetz
authors: Jérôme
authors: J
authors: Lacombe
authors: Alain
authors: A
authors: Mange
authors: Thierry
authors: T
authors: Maudelonde
authors: Jérôme
authors: J
authors: Solassol
mesh_terms: D000912:Antibodies, Neoplasm / Q000097:blood*; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000276:immunology / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood / Q000000981:diagnostic imaging / Q000276:immunology / Q000473:pathology; D003001:Cloning, Molecular / Q000379:methods; D042241:Early Diagnosis; D005260:Female; D005544:Forecasting; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000276:immunology; D008327:Mammography; D008403:Mass Screening; D013058:Mass Spectrometry / Q000379:methods; D009369:Neoplasms / Q000097:blood* / Q000276:immunology; D040901:Proteomics / Q000379:methods; D011994:Recombinant Proteins / Q000276:immunology; D015203:Reproducibility of Results; D012306:Risk; D017422:Sequence Analysis, DNA; D013050:Spectrometry, Fluorescence
chemical_list: D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; D011994:Recombinant Proteins